84 related articles for article (PubMed ID: 25613678)
1. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.
Chen G; Ren H; Zhang N; Lennox W; Turpoff A; Paget S; Li C; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Colacino J; Lahser F; Zhao X; Weetall M; Nomeir A; Karp GM
Bioorg Med Chem Lett; 2015 Feb; 25(4):781-6. PubMed ID: 25613678
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.
Zhang N; Zhang X; Zhu J; Turpoff A; Chen G; Morrill C; Huang S; Lennox W; Kakarla R; Liu R; Li C; Ren H; Almstead N; Venkatraman S; Njoroge FG; Gu Z; Clausen V; Graci J; Jung SP; Zheng Y; Colacino JM; Lahser F; Sheedy J; Mollin A; Weetall M; Nomeir A; Karp GM
J Med Chem; 2014 Mar; 57(5):2121-35. PubMed ID: 24266880
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Structure-Resistance Relationship Study of New Thieno[2,3-
Xiao KJ; Zuo WQ; Xu Y; Tao X; Yu LT; Wang NY
Pharmazie; 2019 Jun; 74(6):321-325. PubMed ID: 31138367
[TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors.
Wang NY; Zuo WQ; Xu Y; Gao C; Zeng XX; Zhang LD; You XY; Peng CT; Shen Y; Yang SY; Wei YQ; Yu LT
Bioorg Med Chem Lett; 2014 Mar; 24(6):1581-8. PubMed ID: 24529869
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-(4'-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication.
Chen G; Ren H; Turpoff A; Arefolov A; Wilde R; Takasugi J; Khan A; Almstead N; Gu Z; Komatsu T; Freund C; Breslin J; Colacino J; Hedrick J; Weetall M; Karp GM
Bioorg Med Chem Lett; 2013 Jul; 23(13):3942-6. PubMed ID: 23683596
[TBL] [Abstract][Full Text] [Related]
8. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM
Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254
[TBL] [Abstract][Full Text] [Related]
9. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
[TBL] [Abstract][Full Text] [Related]
10. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein.
Gu Z; Graci JD; Lahser FC; Breslin JJ; Jung SP; Crona JH; McMonagle P; Xia E; Liu S; Karp G; Zhu J; Huang S; Nomeir A; Weetall M; Almstead NG; Peltz SW; Tong X; Ralston R; Colacino JM
Antimicrob Agents Chemother; 2013 Jul; 57(7):3250-61. PubMed ID: 23629699
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y
Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.
Tai VW; Garrido D; Price DJ; Maynard A; Pouliot JJ; Xiong Z; Seal JW; Creech KL; Kryn LH; Baughman TM; Peat AJ
Bioorg Med Chem Lett; 2014 May; 24(10):2288-94. PubMed ID: 24731273
[TBL] [Abstract][Full Text] [Related]
13. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
Jiang Y; Andrews SW; Condroski KR; Buckman B; Serebryany V; Wenglowsky S; Kennedy AL; Madduru MR; Wang B; Lyon M; Doherty GA; Woodard BT; Lemieux C; Geck Do M; Zhang H; Ballard J; Vigers G; Brandhuber BJ; Stengel P; Josey JA; Beigelman L; Blatt L; Seiwert SD
J Med Chem; 2014 Mar; 57(5):1753-69. PubMed ID: 23672640
[TBL] [Abstract][Full Text] [Related]
14. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally.
Graci JD; Jung SP; Pichardo J; Lahser F; Tong X; Gu Z; Colacino JM
Antimicrob Agents Chemother; 2016 Dec; 60(12):7060-7066. PubMed ID: 27620477
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
Raboisson P; de Kock H; Rosenquist A; Nilsson M; Salvador-Oden L; Lin TI; Roue N; Ivanov V; Wähling H; Wickström K; Hamelink E; Edlund M; Vrang L; Vendeville S; Van de Vreken W; McGowan D; Tahri A; Hu L; Boutton C; Lenz O; Delouvroy F; Pille G; Surleraux D; Wigerinck P; Samuelsson B; Simmen K
Bioorg Med Chem Lett; 2008 Sep; 18(17):4853-8. PubMed ID: 18678486
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.
Chen KX; Vibulbhan B; Yang W; Sannigrahi M; Velazquez F; Chan TY; Venkatraman S; Anilkumar GN; Zeng Q; Bennet F; Jiang Y; Lesburg CA; Duca J; Pinto P; Gavalas S; Huang Y; Wu W; Selyutin O; Agrawal S; Feld B; Huang HC; Li C; Cheng KC; Shih NY; Kozlowski JA; Rosenblum SB; Njoroge FG
J Med Chem; 2012 Jan; 55(2):754-65. PubMed ID: 22148957
[TBL] [Abstract][Full Text] [Related]
18. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT
J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C replication inhibitors that target the viral NS4B protein.
Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ
J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
